Search

Objective: Neonatal diabetes has been shown to be associated with high neuropsychiatric morbidity in a genotype-phenotype-dependent manner. However, the specific impact of different mutations on intellectual functioning is still insufficiently characterized. Specifically, only a small number of subjects with developmental delay have been comprehensively assessed, creating a knowledge gap about patients carrying the heaviest burden.Research Design and Methods: We assessed the intellectual functioning and mental health of the complete Norwegian population with KATP channel neonatal diabetes. Eight sulfonylurea-treated children (five with the p.V59M genotype [KCNJ11]) were assessed using age-matched control subjects with type 1 diabetes. The investigations included a physical and motor developmental examination, cerebral MRI, psychometrical examination, and questionnaires assessing intellectual capabilities and psychiatric morbidity.Results: A strong genotype-phenotype correlation was found, revealing the p.V59M genotype as highly associated with substantial intellectual disability, with no significant correlation with the time of sulfonylurea initiation. Consistent with previous studies, other genotypes were associated with minor cognitive impairment. Cerebral MRI verified normal brain anatomy in all but one child.Conclusions: We here presented a comprehensive assessment of intellectual functioning in the largest cohort of p.V59M subjects to date. The level of intellectual disability revealed not only changes the interpretation of other psychological measures but downplays a strong protective effect of sulfonylurea. Within the scope of this study, we could not find evidence supporting an early treatment start to be beneficial, although a weaker effect cannot be ruled out. [ABSTRACT FROM AUTHOR]

This study aimed to evaluate cerebral magnetic resonance imaging (MRI) scans of children with prenatal drug exposure in a clinical context. A hospital-based cohort of 10- to 14-year-old children, prenatally exposed to alcohol, opioids, and polysubstances, and a group of sex- and age-matched controls were examined with cerebral MRI. Scans obtained from 34 exposed children and 40 controls were scored based on the presence and degree of pathology by an experienced pediatric neuroradiologist blinded to the participants’ background. Overall visual detectable MRI pathology was found in 35% of the exposed children and 33% of the controls (odds ratio = 1.08; 95% confidence interval = 0.36-3.25). No specific imaging pattern following prenatal drug exposure was seen by the means of simple visual analysis of cerebral MRI scans. Although cerebral MRI is feasible, it is probably of limited value in the clinical assessment of children with prenatal drug exposure. [ABSTRACT FROM AUTHOR]

Background: In recent years, the use of opioid maintenance treatment (OMT) during pregnancy has been a topic of much debate among clinicians. A frequent consequence of such therapy is neonatal abstinence syndrome in the newborn infant. This study aimed to investigate whether follow-up of these neonates was in line with national recommendations., Material and Method: All maternity units in Norway were asked whether they treated neonates born to mothers in opioid maintenance treatment (OMT). 14 out of 42 maternity units treated these patients in collaboration with neonatal units, while 28 units referred the patients onward. Altogether 13 of the 14 treatment units answered a questionnaire on the nature of the care received by neonates., Results: None of the hospitals treated more than ten neonates at risk of neonatal abstinence syndrome each year. All neonatal units used a standardised scoring form to assess the development of abstinence. When there was a need for pharmacological treatment, morphine was the first-line choice for all the units. All of them used non-pharmacological interventions. Observation time, procedures for dose reduction of pharmacological treatment and use of supplementary medication varied considerably between the units., Interpretation: Key aspects of the management of neonates born to mothers in opioid maintenance treatment (OMT) were practised in the same manner and in line with national recommendations. However, our study revealed differences between the hospitals, which overall represent a potential for improvement in the treatment of a vulnerable patient group.

Objective: Neonatal diabetes has been shown to be associated with high neuropsychiatric morbidity in a genotype-phenotype-dependent manner. However, the specific impact of different mutations on intellectual functioning is still insufficiently characterized. Specifically, only a small number of subjects with developmental delay have been comprehensively assessed, creating a knowledge gap about patients carrying the heaviest burden., Research Design and Methods: We assessed the intellectual functioning and mental health of the complete Norwegian population with K ATP channel neonatal diabetes. Eight sulfonylurea-treated children (five with the p.V59M genotype [ KCNJ11 ]) were assessed using age-matched control subjects with type 1 diabetes. The investigations included a physical and motor developmental examination, cerebral MRI, psychometrical examination, and questionnaires assessing intellectual capabilities and psychiatric morbidity., Results: A strong genotype-phenotype correlation was found, revealing the p.V59M genotype as highly associated with substantial intellectual disability, with no significant correlation with the time of sulfonylurea initiation. Consistent with previous studies, other genotypes were associated with minor cognitive impairment. Cerebral MRI verified normal brain anatomy in all but one child., Conclusions: We here presented a comprehensive assessment of intellectual functioning in the largest cohort of p.V59M subjects to date. The level of intellectual disability revealed not only changes the interpretation of other psychological measures but downplays a strong protective effect of sulfonylurea. Within the scope of this study, we could not find evidence supporting an early treatment start to be beneficial, although a weaker effect cannot be ruled out., (© 2020 by the American Diabetes Association.)

Background: Musculoskeletal complaints are widespread and a major public health problem in western countries. Prevention and treatment are challenges because the aetiologic factors are not fully understood. Our objective was to estimate the prevalence of and identify possible risk factors for musculoskeletal complaints., Material and Methods: A cross-sectional study including 11 566 men and 13 660 women aged 40-49 and 70-74 who completed a questionnaire in the Hordaland Health Study 1997-99., Results: Musculoskeletal pain and/or stiffness lasting at least three months during the past year was reported by 4461 men (39 %) and 6713 women (49 %). Prevalence among women increased with age. Musculoskeletal complaints were associated with low educational attainment and smoking among both men and women 40-49 years old, and with high body mass index and low physical activity among women. Among the 70-74-year-olds, complaints were associated with low educational attainment among men and with smoking, high body mass index and low physical activity among women. A dose-response relationship between smoking and musculoskeletal complaints was found, with a stronger effect among women than men., Interpretation: Musculoskeletal complaints were common, the prevalence higher among women than men. The results indicate that musculoskeletal complaints may be prevented or reduced by smoking cessation.